Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 17/20 | 0.68 |
| ▸ | JAK2 | O60674 | 15/20 | 0.68 |
| ▸ | ROCK1 | Q13464 | 15/20 | 0.68 |
| ▸ | JAK3 | P52333 | 13/20 | 0.68 |
| ▸ | IKBKB | O14920 | 8/20 | 0.68 |
| ▸ | JAK1 | P23458 | 5/20 | 0.68 |
| ▸ | TYK2 | P29597 | 5/20 | 0.68 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20353563 | 0.92 | ROCK2 (0.69) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL22751939 | 0.90 | ROCK2 (0.68) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL20524967 | 0.90 | ROCK2 (0.68) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL29728123 | 0.90 | ROCK2 (0.68) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL20525018 | 0.90 | ROCK2 (0.67) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL22752151 | 0.90 | ROCK2 (0.68) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL25478352 | 0.89 | ROCK2 (0.76) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL12465048 | 0.89 | ROCK2 (0.76) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL3613021 | 0.89 | ROCK2 (0.76) | ROCK2JAK2ROCK1JAK3IKBKB | |
| SCHEMBL2163450 | 0.89 | ROCK2 (0.76) | ROCK2JAK2ROCK1JAK3IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210002253-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2021-01-07 | — | — | US | disclosed |
| US-10858339-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002253-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | ROCK2 219/4885JAK2 268/4885ROCK1 278/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | ROCK2 219/4885JAK2 268/4885ROCK1 278/4885 |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | ROCK2 219/4885JAK2 268/4885ROCK1 278/4885 |
| US-10858339-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | ROCK2 219/4885JAK2 268/4885ROCK1 278/4885 |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | ROCK2 219/4885JAK2 268/4885ROCK1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.